| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Sec-O-Glucosylhamaudol targets the p38 MAPK signaling pathway. By regulating this pathway, it reduces the inflammatory response in macrophages. It also interacts with the μ-opioid receptor system, as it has been shown to reduce the protein level of μ-opioid receptors. This suggests a dual mechanism of action involving both anti-inflammatory and analgesic pathways. Its primary targets are therefore p38 MAPK and the μ-opioid receptor.
|
|---|---|
| ln Vitro |
In vitro, Sec-O-Glucosylhamaudol has been shown to exert anti-inflammatory effects through the regulation of p38 MAPK in LPS-stimulated RAW264.7 macrophage cells. This regulation likely involves the inhibition of p38 phosphorylation, leading to a reduction in the production of pro-inflammatory cytokines. It also reduces the protein level of μ-opioid receptors. These in vitro studies demonstrate its anti-inflammatory and potential analgesic activities.
|
| ln Vivo |
In vivo, Sec-O-Glucosylhamaudol has been shown to have a very strong antinociceptive effect when administered intrathecally. This suggests that it can effectively reduce pain in animal models. Its anti-inflammatory effects are also expected to be observed in vivo. However, detailed in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, are limited in the available sources. Further research is needed to fully characterize its in vivo activity.
|
| Enzyme Assay |
For cell-free enzyme assays, the anti-inflammatory activity of Sec-O-Glucosylhamaudol can be studied by measuring its effect on p38 MAPK activity. A kinase activity assay can be performed using purified p38 MAPK and a specific substrate. The compound is incubated with the kinase and substrate in the presence of ATP, and the phosphorylation of the substrate is measured. Its interaction with the μ-opioid receptor can be studied using radioligand binding assays.
|
| Cell Assay |
For in vitro cellular assays, the anti-inflammatory activity of Sec-O-Glucosylhamaudol is assessed in LPS-stimulated RAW264.7 macrophage cells. Cells are treated with varying concentrations of the compound and stimulated with LPS. The phosphorylation of p38 MAPK is measured by Western blot using phospho-specific antibodies. The production of pro-inflammatory cytokines, such as TNF-α and IL-6, is measured by ELISA. Its effect on μ-opioid receptor levels is assessed by Western blot.
|
| Animal Protocol |
For in vivo studies, the antinociceptive effect of Sec-O-Glucosylhamaudol is typically evaluated in rodent models of pain. The compound is administered intrathecally or systemically. Pain responses are measured using tests such as the tail-flick test or the formalin test. Its anti-inflammatory effect can be assessed in models of acute or chronic inflammation, such as carrageenan-induced paw edema.
|
| ADME/Pharmacokinetics |
Sec-O-Glucosylhamaudol has a molecular formula of C21H26O10 and a molecular weight of 438.43 g/mol. Its CAS number is 80681-44-3. It is a chromone glycoside and is typically supplied as a powder. It is soluble in DMSO and ethanol. For in vitro studies, stock solutions are prepared in DMSO. For in vivo administration, it can be formulated in suitable vehicles. Storage is recommended at 2-8°C. Its purity is typically >95% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural chromone glycoside from a plant with a history of medicinal use, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that the observed effects are not due to a general reduction in cell viability.
|
| References | |
| Additional Infomation |
Sek-O-glucosylhamool is a type of chromene compound. It has been reported that sek-O-glucosylhamool exists in Japanese angelica, large-leaved parsley, and other organisms with relevant data.
Sec-O-Glucosylhamaudol is a research-grade compound and is not approved for any therapeutic use. It serves primarily as a valuable pharmacological tool and a reference standard for studying inflammation and pain. Its mechanism of action involves the regulation of p38 MAPK and a reduction in μ-opioid receptor protein levels. Its anti-inflammatory and antinociceptive activities make it a compound of interest for drug discovery. No clinical trials have been reported. |
| Molecular Formula |
C21H26O10
|
|---|---|
| Molecular Weight |
438.4251
|
| Exact Mass |
438.152
|
| CAS # |
80681-44-3
|
| PubChem CID |
10478277
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
677.5±55.0 °C at 760 mmHg
|
| Flash Point |
237.2±25.0 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.661
|
| LogP |
0.39
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
723
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC1=CC(=O)C2=C(C3=C(C=C2O1)OC([C@H](C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)(C)C)O
|
| InChi Key |
QVUPQEXKTXSMKX-JJDILSOYSA-N
|
| InChi Code |
InChI=1S/C21H26O10/c1-8-4-10(23)15-12(28-8)6-11-9(16(15)24)5-14(21(2,3)31-11)30-20-19(27)18(26)17(25)13(7-22)29-20/h4,6,13-14,17-20,22,24-27H,5,7H2,1-3H3/t13-,14+,17-,18+,19-,20+/m1/s1
|
| Chemical Name |
(3S)-5-hydroxy-2,2,8-trimethyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydropyrano[3,2-g]chromen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~228.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2809 mL | 11.4043 mL | 22.8087 mL | |
| 5 mM | 0.4562 mL | 2.2809 mL | 4.5617 mL | |
| 10 mM | 0.2281 mL | 1.1404 mL | 2.2809 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
